Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer

Trial Profile

A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Aravive S6 (Primary) ; Doxorubicin liposomal; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aravive; Aravive Biologics
  • Most Recent Events

    • 11 Dec 2018 According to an Aravive Biologics media release, company has begun treating patients in the phase 1b portion of this trial.
    • 04 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 13 Nov 2018 According to a Versartis media release, based on the data of NCT03401528, company has selected the 10 mg/kg every other week as the initial dose in this trial, and expected to enroll first patient before the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top